PVLA
Neutral signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Financial indicators Supports a bullish reading. Current ratio 5.20 · operating margin 0.0%
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Supports a bullish reading. Interesting trend — weekly bias up
VENTE TOTALE: 27 813 titres (~4 200 219,24 $ US)
- Insiders
- JENKINS GEORGE MKIRITSY CHRISTOPHER P
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$4,200,219
Avg sell (VWAP, 90d window) $152.58 vs last close $138.16 (-9.5%)
- Last activity
- 2026-09-15
- Liquidity
- Liquid $29,312,178/day · 20d vol
- Last synced
-
2026-09-25 21:10:50
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-16 | Goin Kathleen | Sell | 1,654 | $153.24 | $253,465 | Form 4 |
| 2026-09-15 | JENKINS GEORGE M | Sell | 560 | $151.33 | $84,743 | Form 4 |
| 2026-09-14 | JENKINS GEORGE M | Sell | 1,560 | $153.10 | $238,834 | Form 4 |
| 2026-09-11 | JENKINS GEORGE M | Sell | 1,274 | $153.06 | $194,997 | Form 4 |
| 2026-09-02 | KIRITSY CHRISTOPHER P | Sell | 313 | $157.00 | $49,141 | Form 4 |
| 2026-08-19 | Goin Kathleen | Sell | 302 | $156.77 | $47,345 | Form 4 |
| 2026-07-15 | Goin Kathleen | Sell | 1,911 | $150.25 | $287,133 | Form 4 |
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Neutral signalScored 2026-09-21
PVLA presents a deeply conflicted profile: while the completed rolling NDA submission to the FDA for QTORIN is a meaningful binary catalyst with a potential 2027 approval horizon, the company is a pre-revenue shell with…
The first sentence of the analysis written for PVLA on 2026-09-21 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 89.3% | 92.5% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | -128.5% | -145.6% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | -117.7% | -138.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | -167.8% | -165.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | -128.5% | -145.6% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | -128.5% | -145.6% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | -128.5% | -145.6% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | -128.5% | -145.6% | |
| Current Ratio | 5.200 | 7.330 | 3.198 | 2.858 | 2.524 | |
| Quick Ratio | 5.200 | 7.330 | 3.198 | 2.858 | 2.524 | |
| Solvency Ratio | -1.321 | -0.680 | 1.636 | -0.768 | -0.422 | |
| Cash Ratio | 5.111 | 6.945 | 3.114 | 2.776 | 2.329 | |
| Price To Earnings Ratio | -28.213 | -1.533 | 1.153 | -0.574 | -0.300 | |
| Price To Earnings Growth Ratio | 0.536 | 0.010 | -0.008 | 0.012 | 0.000 | |
| Forward Price To Earnings Growth Ratio | 0.536 | 0.010 | -0.008 | 0.012 | 0.000 | |
| Price To Earnings Diluted Ratio | -28.213 | -1.533 | 1.153 | -0.574 | -0.300 | |
| Price To Earnings Diluted Growth Ratio | 0.536 | 0.010 | -0.008 | 0.012 | 0.000 | |
| Price To Book Ratio | 42.085 | 0.427 | -5.556 | -0.682 | 0.270 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.611 | 0.437 | |
| Price To Free Cash Flow Ratio | -47.095 | -2.464 | -1.573 | -1.066 | -1.593 | |
| Price To Operating Cash Flow Ratio | -47.095 | -2.464 | -1.573 | -1.066 | -1.791 | |
| Debt To Assets Ratio | 0.011 | 0.000 | 0.000 | 0.000 | 0.097 | |
| Debt To Equity Ratio | 0.023 | 0.000 | 0.000 | 0.000 | 0.293 | |
| Debt To Capital Ratio | 0.022 | 0.000 | 0.000 | 0.000 | 0.227 | |
| Long Term Debt To Capital Ratio | 0.015 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 2.128 | 1.409 | -1.945 | -0.713 | 3.026 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.590 | 0.481 | |
| Operating Cash Flow Ratio | -2.204 | -0.900 | -5.806 | -2.567 | -0.152 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | -0.573 | -0.244 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.000 | 1.000 | 1.000 | 1.124 | |
| Debt Service Coverage Ratio | -6.170 | -3.038 | 0.000 | 0.000 | -41.344 | |
| Interest Coverage Ratio | -6.635 | -3.265 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | -7.302 | |
| Operating Cash Flow Coverage Ratio | -39.504 | 0.000 | 0.000 | 0.000 | -0.514 | |
| Capital Expenditure Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | -8.072 | |
| Dividend Paid And Capex Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | -8.072 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -31.209 | 4.337 | 0.760 | 0.008 | 2.056 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | ▼-36.4% |
| Ebit Margin | 0.0% | 0.0% | ▲54.8% |
| Ebitda Margin | 0.0% | 0.0% | ▲51.2% |
| Operating Profit Margin | 0.0% | 0.0% | ▲66.6% |
| Pretax Profit Margin | 0.0% | 0.0% | ▲54.8% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | ▲54.8% |
| Net Profit Margin | 0.0% | 0.0% | ▲54.8% |
| Bottom Line Profit Margin | 0.0% | 0.0% | ▲54.8% |
| Current Ratio | 5.200 | ▼-2.130 | ▲0.978 |
| Quick Ratio | 5.200 | ▼-2.130 | ▲0.978 |
| Solvency Ratio | -1.321 | ▼-0.641 | ▼-1.010 |
| Cash Ratio | 5.111 | ▼-1.834 | ▲1.056 |
| Price To Earnings Ratio | -28.213 | ▼-26.680 | ▼-22.320 |
| Price To Earnings Growth Ratio | 0.536 | ▲0.526 | ▲0.426 |
| Forward Price To Earnings Growth Ratio | 0.536 | ▲0.526 | ▲0.426 |
| Price To Earnings Diluted Ratio | -28.213 | ▼-26.680 | ▼-22.320 |
| Price To Earnings Diluted Growth Ratio | 0.536 | ▲0.526 | ▲0.426 |
| Price To Book Ratio | 42.085 | ▲41.658 | ▲34.776 |
| Price To Sales Ratio | 0.000 | 0.000 | ▼-0.209 |
| Price To Free Cash Flow Ratio | -47.095 | ▼-44.631 | ▼-36.337 |
| Price To Operating Cash Flow Ratio | -47.095 | ▼-44.631 | ▼-36.298 |
| Debt To Assets Ratio | 0.011 | ▲0.011 | ▼-0.011 |
| Debt To Equity Ratio | 0.023 | ▲0.023 | ▼-0.041 |
| Debt To Capital Ratio | 0.022 | ▲0.022 | ▼-0.028 |
| Long Term Debt To Capital Ratio | 0.015 | ▲0.015 | ▲0.012 |
| Financial Leverage Ratio | 2.128 | ▲0.719 | ▲1.347 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | ▼-0.214 |
| Operating Cash Flow Ratio | -2.204 | ▼-1.304 | ▲0.121 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | ▲0.163 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 0.000 | ▼-0.025 |
| Debt Service Coverage Ratio | -6.170 | ▼-3.131 | ▲3.941 |
| Interest Coverage Ratio | -6.635 | ▼-3.370 | ▼-4.655 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲1.460 |
| Operating Cash Flow Coverage Ratio | -39.504 | ▼-39.504 | ▼-31.500 |
| Capital Expenditure Coverage Ratio | 0.000 | 0.000 | ▲1.614 |
| Dividend Paid And Capex Coverage Ratio | 0.000 | 0.000 | ▲1.614 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -31.209 | ▼-35.546 | ▼-26.400 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.18B | $26.7M | $21.6M | $15.8M | $13.7M | |
| Enterprise value | $1.12B | -$56.9M | $14.2M | -$237K | -$89.2M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | -0.01x | -2.84x | |
| EV / Op. cash flow | -44.80x | 5.25x | -1.04x | 0.02x | 11.64x | |
| EV / Free cash flow | -44.80x | 5.25x | -1.04x | 0.02x | 10.36x | |
| EV / EBITDA | -31.21x | 4.34x | 0.76x | 0.01x | 2.06x | |
| Net debt / EBITDA | 1.60x | 6.37x | -0.39x | 0.53x | 2.37x | |
| Current ratio | 5.20x | 7.33x | 3.20x | 2.86x | 2.52x | |
| Income quality | 0.60x | 0.62x | -0.73x | 0.54x | 0.17x | |
| Graham net-net | $2 | $27 | -$3 | -$25 | $22 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 116.2% | 132.9% | 100.0% | 100.0% | 100.0% | |
| Working capital | $47.6M | $76.2M | $5.2M | $10.7M | $77.1M | |
| Invested capital | $48.2M | $76.2M | $5.2M | $10.7M | $100.1M | |
| Return on assets | -70.0% | -19.8% | 247.6% | -201.4% | -29.8% | |
| Operating ROA | -52.2% | -29.4% | -98.6% | -51.1% | -40.1% | |
| Return on tangible assets | -70.0% | -19.8% | 247.6% | -201.4% | -29.8% | |
| Return on equity | -149.1% | -27.8% | -481.7% | 143.6% | -90.1% | |
| Return on invested capital | -79.7% | -18.5% | -228.8% | -404.7% | -49.8% | |
| Return on capital employed | -80.1% | -18.5% | -228.8% | -404.7% | -50.3% | |
| Earnings yield | -3.5% | -65.3% | 86.7% | -210.4% | -333.5% | |
| Free cash flow yield | -2.1% | -40.6% | -63.6% | -93.8% | -62.8% | |
| Capex / Op. cash flow | 0.0% | 0.0% | 0.0% | 0.0% | -12.4% | |
| Capex / Depreciation | 0.0% | 0.0% | 0.0% | 0.0% | 40.1% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 3.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 63.3% | 53.1% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 193.9% | 204.3% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 1.6% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 38d | |
| Days payables outstanding | 0d | 0d | 0d | 418d | 1327d | |
| Operating cycle | 0d | 0d | 0d | 0d | 38d | |
| Cash conversion cycle | 0d | 0d | 0d | -418d | -1288d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+4308.8%EV / Sales n/aEV / EBITDA ▼-819.6%EV / Op. cash flow ▼-50.050Earnings yield ▲+0.617
Profitability
Return on equity ▼-1.212Return on assets ▼-0.503Return on invested capital ▼-0.612Return on capital employed ▼-0.616Operating ROA ▼-0.228Income quality ▼-0.022Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-2.130Net debt / EBITDA ▼-4.776Working capital ▼-28553000.000Invested capital ▼-27981000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+8485.9%EV / Sales ▲+100.0%EV / EBITDA ▼-1618.1%EV / Op. cash flow ▼-56.441Earnings yield ▲+3.299
Profitability
Return on equity ▼-0.590Return on assets ▼-0.403Return on invested capital ▼-0.299Return on capital employed ▼-0.297Operating ROA ▼-0.121Income quality ▲+0.432Tax burden 0.000
Efficiency
Days sales outstanding ▼-38.489Days payables outstanding ▼-1326.978Operating cycle ▼-38.489Cash conversion cycle ▲+1288.490Capex / Sales ▼-0.030R&D / Sales ▼-2.043
Balance-sheet strength
Current ratio ▲+2.676Net debt / EBITDA ▼-0.774Working capital ▼-29421000.000Invested capital ▼-51880000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent news
- 2026-09-09 Palvella Therapeutics Appoints James R. Treat, M.D. Brings expertise in cutaneous vascular anomalies, including microcystic lymphatic malformations, venous malformations and angiokeratomas
- 2026-09-02 Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences WAYNE, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will participate in two upcoming healthcare investor conferences.
- 2026-08-31 Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations QTORIN™ rapamycin has the potential to become the first FDA-approved therapy and establish a new standard of care for an estimated more than 30,000 pediatric and adult patients living with microcystic lymphatic malformations in the U.S.
- 2026-08-29 Bank of America Corp DE Has $4.73 Million Holdings in Palvella Therapeutics, Inc. $PVLA Bank of America Corp DE grew its stake in shares of Palvella Therapeutics, Inc. (NASDAQ: PVLA) by 25.4% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 37,972 shares of the company''s stock after buying an additional 7,700 shares during the quarter. Bank
- 2026-08-18 Palvella Therapeutics: First Approval Could Unlock A Rare-Disease Commercial Flywheel Palvella advances QTORIN rapamycin, targeting microcystic lymphatic malformations, with positive Phase 3 SELVA data and a rolling NDA submission underway. PVLA leverages a repeatable regulatory and commercial platform, aiming to expand QTORIN across multiple mTOR-driven dermatological indications, supporting a multi-indication commercial flywheel. Strong liquidity from a recent $230M equity raise enables PVLA to invest in commercialization and pipeline expansion, mitigating typical small biotech funding risks.
- 2026-08-16 Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands Palvella Therapeutics NASDAQ: PVLA is advancing topical therapies for serious rare skin diseases and vascular malformations that lack FDA-approved treatments, with its lead candidate, QTORIN rapamycin, moving toward a planned New Drug Application submission for microcystic lymphatic malformations.
- 2026-08-06 Palvella Therapeutics Q2 Earnings Call Highlights Palvella Therapeutics (NASDAQ: PVLA) said it remains on track to complete its new drug application submission for QTORIN rapamycin in microcystic lymphatic malformations, or mLM, during the second half of 2026, with potential FDA approval targeted for the first half of 2027. The company has submitted the first module of its NDA after the FDA granted
- 2026-08-05 Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference WAYNE, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, announced today that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 3:30 p.m. ET.
- 2026-08-04 Palvella Therapeutics, Inc. (PVLA) Q2 2026 Earnings Call Transcript Palvella Therapeutics, Inc. (PVLA) Q2 2026 Earnings Call Transcript
- 2026-08-04 Palvella Therapeutics Q2 Earnings Call Highlights Palvella Therapeutics NASDAQ: PVLA said it remains on track to complete its new drug application submission for QTORIN rapamycin in microcystic lymphatic malformations, or mLM, during the second half of 2026, with potential FDA approval targeted for the first half of 2027.